Antiretroviral drug concentrations in semen of HIV-1 infected men
about
Quantification of antiretroviral drugs for HIV-1 in the male genital tract: current data, limitations and implications for laboratory analysis.High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.HIV infection of the male genital tract--consequences for sexual transmission and reproduction.Intracellular accumulation of human immunodeficiency virus protease inhibitorsChemoprophylaxis for HIV prevention: new opportunities and new questions.Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapyTiming of intermittent seminal HIV-1 RNA shedding in patients with undetectable plasma viral load under combination antiretroviral therapy.Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.The male genital tract is not a pharmacological sanctuary from efavirenz.Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitroHIV treatment as prevention and HPTN 052.Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives.Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment.Novel methodology for antiretroviral quantitation in the female genital tractImpact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen.Patterns of residual HIV-1 RNA shedding in the seminal plasma of patients on effective antiretroviral therapy.Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.Characterization of binding of raltegravir to plasma proteinsDifferences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract.Correlation of in vitro and in vivo plasma protein binding using ultracentrifugation and UPLC-tandem mass spectrometry.ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.Antiretroviral Therapy and Alcohol Interactions: X-raying Testicular and Seminal Parameters Under the HAART Era.Noninvasive quantitation of drug concentration in prostate and seminal vesicles: improvement and validation with desipramine and aspirin.KAE609 (Cipargamin), a New Spiroindolone Agent for the Treatment of Malaria: Evaluation of the Absorption, Distribution, Metabolism, and Excretion of a Single Oral 300-mg Dose of [14C]KAE609 in Healthy Male Subjects.Predictive models for drugs exhibiting negative food effects based on their biopharmaceutical characteristics.Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.
P2860
Q31135042-0DD1BC39-F9E7-4482-8A42-C9C879EB6A65Q33613775-3047F46B-B3B2-431C-8E87-A774E708A489Q33629797-58324E3C-A512-4B0D-80EC-7178675926B4Q34143531-F29698F3-F106-4F43-A5F5-21868E948DE8Q34786284-A830FC80-5A83-41FA-9F65-023F00813E61Q35077988-51EB039B-ADFD-4440-958D-97FE4B78CDA8Q35110885-F627DF50-96E8-4400-B48F-D6377388E33FQ35547967-8190D08F-C2DA-41DD-8252-738218DFF16BQ35548422-EC7B9CA4-A636-4B2E-9451-911050DEBB4FQ35569867-42DA40F7-ED40-45EE-A8EF-E67377F2539CQ36364604-C06C5080-8E03-4BB8-9AA0-0EAC12C4CFBBQ36891072-B07A9321-2517-4C6F-9812-8D55876AA7D8Q36929418-70D98C38-0E1A-4322-A09E-F7164EA3DBD8Q37158604-93380B76-6FD2-4998-B4F5-D28BDA30878DQ39328033-8C2D290D-7448-43C6-BAFE-96E920A19C9FQ40042087-AA158813-BCF6-44FE-AD73-1F86E6429445Q42375999-EDD1EFAB-9CA4-4037-BCC0-218DCF69C127Q42605087-A34668F7-6D19-4272-97DF-40B18613A9CDQ43871660-E091FBBA-74DB-46D6-BD05-09AE1AFE8F12Q45381621-8A4E3FFC-4E27-4680-AB56-E5762F6D9329Q45917670-8E4985A8-B9F9-4215-981B-34F46F7481DCQ46126663-07D7EDBA-22EA-4CD4-AC54-7E9BB273A70AQ46496164-B4905541-B893-4E14-B249-6ED803BC0BB1Q46840696-EEA27D42-98B7-4A30-86F7-9E9AF541FEC3Q47949881-7A15FA89-670A-4B50-86F7-345C7F894305Q51564625-843C3371-914B-4436-81E0-43F9A70A622AQ53403180-886F6455-0B37-43B5-BC03-416B7CE92D25
P2860
Antiretroviral drug concentrations in semen of HIV-1 infected men
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antiretroviral drug concentrations in semen of HIV-1 infected men
@ast
Antiretroviral drug concentrations in semen of HIV-1 infected men
@en
Antiretroviral drug concentrations in semen of HIV-1 infected men
@nl
type
label
Antiretroviral drug concentrations in semen of HIV-1 infected men
@ast
Antiretroviral drug concentrations in semen of HIV-1 infected men
@en
Antiretroviral drug concentrations in semen of HIV-1 infected men
@nl
prefLabel
Antiretroviral drug concentrations in semen of HIV-1 infected men
@ast
Antiretroviral drug concentrations in semen of HIV-1 infected men
@en
Antiretroviral drug concentrations in semen of HIV-1 infected men
@nl
P2860
P356
P1476
Antiretroviral drug concentrations in semen of HIV-1 infected men
@en
P2093
P2860
P356
10.1136/STI.77.1.4
P577
2001-02-01T00:00:00Z